Last kr19.70 SEK
Change Today +0.30 / 1.55%
Volume 114.0K
OASM On Other Exchanges
Symbol
Exchange
Stockholm
Frankfurt
As of 11:30 AM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

oasmia pharmaceutical ab (OASM) Snapshot

Open
kr19.50
Previous Close
kr19.40
Day High
kr19.80
Day Low
kr19.20
52 Week High
02/19/14 - kr31.00
52 Week Low
10/13/14 - kr16.34
Market Cap
1.9B
Average Volume 10 Days
45.8K
EPS TTM
kr-1.27
Shares Outstanding
97.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OASMIA PHARMACEUTICAL AB (OASM)

Related News

No related news articles were found.

oasmia pharmaceutical ab (OASM) Related Businessweek News

No Related Businessweek News Found

oasmia pharmaceutical ab (OASM) Details

Oasmia Pharmaceutical AB (publ) researches, develops, and manufactures drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company’s drug candidates for human health include Paclical that has completed Phase III clinical trial for the treatment of ovarian cancer, as well as is in Phase I clinical trial for treating metastatic breast cancer; Doxophos, a formulation of the cytostatic doxorubicin in Phase I clinical trial for the treatment of cancer; Docecal, a patented formulation of cytostatic docetaxel, which is in pre-clinical stage for the treatment of breast cancer; and OAS-19 that is in pre-clinical stage to treat various cancers. Its product candidates for animal health comprise Paccal Vet-CA1, a formulation of paclitaxel for the treatment of mastocytoma, mammary carcinoma, and squamous cell carcinoma in dogs; and Doxophos Vet, a Phase I clinical trial product for the treatment of lymphoma in dogs. Oasmia Pharmaceutical AB was founded in 1990 and is based in Uppsala, Sweden.

75 Employees
Last Reported Date: 12/4/14
Founded in 1990

oasmia pharmaceutical ab (OASM) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: kr1.3M
Compensation as of Fiscal Year 2014.

oasmia pharmaceutical ab (OASM) Key Developments

Oasmia Pharmaceutical AB (publ)(OM:OASM) dropped from OMX Nordic Small Cap Index

Oasmia Pharmaceutical AB (publ) will be removed from OMX Nordic Small Cap Index.

Oasmia Pharmaceutical AB (publ) Reports Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended October 31, 2014

Oasmia Pharmaceutical AB (publ) reported consolidated and parent earnings results for the second quarter and six months ended October 31, 2014. For the quarter, on consolidated basis, the company reported net sales of SEK 558,000 against SEK 24,000 a year ago. Operating loss was SEK 24,145,000 against SEK 17,374,000 a year ago. Loss before taxes was SEK 26,715,000 against SEK 18,661,000 a year ago. Loss for the period attributable to shareholders of the parent company was SEK 26,715,000 or SEK 0.30 per basic and diluted share against SEK 18,661,000 or SEK 0.23 per basic and diluted share a year ago. Cash flow used in operating activities was SEK 24,637,000 against SEK 18,457,000 a year ago. Investments in intangible assets were SEK 5,729,000 against SEK 9,487,000 a year ago. Investments in property, plant and equipment was SEK 587,000 against SEK 34,000 a year ago For the six months, on consolidated basis, the company reported net sales of SEK 1,552,000 against SEK 24,000 a year ago. Operating loss was SEK 54,496,000 against SEK 34,359,000 a year ago. Loss before taxes was SEK 59,704,000 against SEK 36,885,000 a year ago. Loss for the period attributable to shareholders of the parent company was SEK 59,704,000 or SEK 0.69 per basic and diluted share against SEK 36,885,000 or SEK 0.45 per basic and diluted share a year ago. Cash flow used in operating activities was SEK 55,695,000 against SEK 34,157,000 a year ago. Investments in intangible assets were SEK 10,230,000 against SEK 17,887,000 a year ago. Investments in property, plant and equipment was SEK 2,014,000 against SEK 62,000 a year ago. Net debt as at October 31, 2014 was SEK 117,865,000 compared to SEK 94,149,000 as at October 31, 2013. For the quarter, on parent basis, the company reported net sales of SEK 558,000 against SEK 24,000 a year ago. Operating loss was SEK 24,140,000 compared to SEK 17,362,000 a year ago. Loss for the period was SEK 26,710,000 compared to SEK 18,679,000 a year ago. For the six months, on parent basis, the company reported net sales of SEK 1,552,000 against SEK 24,000 a year ago. Operating loss was SEK 54,487,000 compared to SEK 34,330,000 a year ago. Loss for the period was SEK 59,695,000 compared to SEK 36,887,000 a year ago.

Oasmia Pharmaceutical AB (publ) Reports Consolidated and Parent Earnings Results for the First Quarter Ended July 31, 2014

Oasmia Pharmaceutical AB (publ) reported consolidated and parent earnings results for the first quarter ended July 31, 2014. For the period, on consolidated the company reported operating loss of SEK 30,351,000 compared with SEK 16,985,000 for the same period last year. Loss for the period attributable to shareholders of the parent company was SEK 32,989,000 or SEK 0.38 per share before and after dilution compared with SEK 18,224,000 or SEK 0.22 per share before and after dilution for the same period last year. Cash flow from used in operating activities amounted to SEK 31,058,000 compared SEK 15,700,000 for the same period last year. The decrease compared to the corresponding period previous year is attributable to a significant decrease in operating income and a slight increase in working capital. Loss before taxes was SEK 32,989,000 compared with SEK 18,224,000 for the same period last year. Investments in intangible fixed assets were SEK 4,501,000 against SEK 8,400,000 a year ago. Investments in property, plant and equipment was SEK 1,426,000 against SEK 28,000 a year ago. Net sales were SEK 994,000. Net debt was SEK 9,418,000 against SEK 7,170,000 a year ago. For the period, on parent basis the company reported operating loss of SEK 30,347,000 compared with SEK 16,968,000 for the same period last year. Loss for the period was SEK 32,985,000 compared with SEK 18,207,000 for the same period last year. Net sales were SEK 994,000. Net loss before tax amounted to SEK 32,985,000 against SEK 18,207,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OASM:SS kr19.70 SEK +0.30

OASM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OASM.
View Industry Companies
 

Industry Analysis

OASM

Industry Average

Valuation OASM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 61.0x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 61.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OASMIA PHARMACEUTICAL AB, please visit www.oasmia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.